Novo Nordisk (NOVOb.CO) warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photowarned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.
Novo's words of caution, earlier reported by Danish publication Finans, amounted to the first detailed comments from the group on the counterfeit issue since a mid-June statement about fake Ozempic pens found at a U.S. retail That company in turn had received the consignment from a peer in Austria, the prosecutors said, adding that investigators are trying to find out whether more fakes had been sold in Germany.
The Danish drugmaker also said it was working with a third party specialized in monitoring and taking down illegal online offers. It scaled up this work in 2023 to ensure a broader reach, it said, declining to name the firm it was working with.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Novo Nordisk, Eli Lilly leap as Ozempic show promise in kidney patient treatmentOzempic, the diabetes treatment often prescribed for weight loss, is also proving highly-effective in treating patients with chronic kidney disease.
Baca lebih lajut »
Novo Nordisk stops Ozempic kidney trial after early signs of successNovo Nordisk (NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Baca lebih lajut »
Stock movers: DaVita, Exxon Mobil, Ozempic drug parent Novo NordiskExxon Mobil stock falls after the oil giant announces a $59.5 billion all-stock deal to buy Pioneer Natural Resources
Baca lebih lajut »
Why are businesses bracing for changes thanks to new weight loss drugs?The popularity of Ozempic and Wegovy could change how companies operate.
Baca lebih lajut »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon, Amgen and moreThese are some of the stocks posting the largest moves midday.
Baca lebih lajut »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and moreThese are some of the stocks posting the largest moves midday.
Baca lebih lajut »